by chalipeter • • Comments Off on Malaria vaccine RTS,S/AS01E
An epidemiology study to assess Plasmodium falciparumparasite prevalence and serological conversion rates in catchment areas of a Phase III trial of the candidate malaria vaccine RTS,S/AS01E in sub-Saharan Africa
Collaborating institutions:GSK, PATH-MVI, CMP and LSHTM.
Objective:To obtain longitudinal estimates of parasite rate (PR) in order to characterize in a standardized way malaria transmission intensity at different clinical trial centers participating in GSK’s pivotal Phase III candidate malaria vaccine trial in sub-Saharan Africa.
Study area: Korogwe and Handeni Districts, Tanga Region